Should I buy Neo stock in 2025?

What is Neo?

How much is the Neo stock?

The price of Neo stock is falling this week. As of now, Neo trades at $7.37 USD, with a 24-hour change of -0.67% and a weekly decrease of -0.54%. The company’s current market capitalisation stands at $948.48 million, and its average daily trading volume over the past 3 months is 2.06 million shares. No P/E Ratio is available due to ongoing losses, and the dividend yield is 0.00%. With a stock beta of 1.60, Neo remains especially sensitive to broader market swings—investors in Ireland should be prepared for notable volatility ahead.

Our full analysis of the Neo stock

After reviewing NeoGenomics Inc. (NEO) and thoroughly analysing its latest quarterly results, stock price evolution over the last three years, and an array of technical, fundamental, and market datasets through our proprietary models, Neo stands out as an intriguing candidate in the diagnostics and precision oncology sector. By integrating established financial indicators, technical signals, peer benchmarking, and broader sectoral drivers, we uncover several compelling dynamics behind the current valuation, strategic shifts, and positive undercurrents for NEO. So, why might NeoGenomics stock once again represent a strategic entry point into specialized diagnostics in 2025?

Recent Performance and Market Context

NeoGenomics has experienced a challenging twelve months, with its share price down -46.71% over the past year and off -58.43% over six months, currently trading at $7.37 on the NASDAQ as of 30 May 2025. The broader healthcare diagnostics sector has faced profit-taking amid industry-wide rotation and macroeconomic volatility, yet recent events highlight an important inflection phase for NEO.

Three major positive developments have buoyed market sentiment:

• Executive Reshuffle: The appointment of Chris Zook as CEO in April 2025 introduces an experienced leader with a record of operational improvement and focused strategic execution, reassuring both institutional and retail investors.
• Product Innovation: The debut of the PanTracer diagnostic test suite at ASCO 2025 positions Neo at the forefront of next-generation cancer detection, reinforcing its commitment to innovation and expanding its addressable market.
• Insider Confidence: Multiple C-suite insiders have made notable share purchases in recent weeks, signalling management's confidence in the turnaround efforts and future prospects.

Additionally, the macroeconomic and demographic landscape for oncology diagnostics remains robust, driven by an aging population and growth in personalised medicine. The consensus analyst price target of $10.62 (mean, with an upper range to $15.00) indicates the investment community is beginning to anticipate an improving scenario.

Technical Analysis

Although NEO shares are presently trading below their primary moving averages—20-day ($8.45), 50-day ($8.71), and 200-day ($13.25)—this technically oversold zone can often foreshadow bottoming-out and reversion opportunities:

• Support Levels: The recent lows near $6.08 serve as a strong technical base, evident from robust buying support when the price approaches these levels.
• Resistance Zones: Short-term resistance ranges between $8.67 and $9.15. A breakout above this zone could trigger momentum-driven interest, with scope for a rally towards historical highs.
• Momentum and Oscillators: Although the stock is navigating a short- and medium-term bearish structure, momentum indicators (e.g., RSI dips and flattening MACD) are beginning to flash early signals of stabilization. The stock’s high beta (1.60) could amplify recovery if broader markets stabilize.
• Volume Patterns: Despite near-term pressure, average trading volume remains elevated at 2.06M shares daily, reflecting persistent institutional engagement and underlying liquidity strength.

Combined, these signals suggest Neo is approaching a technically attractive level, with risk/reward becoming increasingly favourable for new capital deployment ahead of forthcoming operational catalysts.

Fundamental Analysis

At a fundamental level, NeoGenomics displays several hallmarks of a nimble, high-potential growth company in the midst of a multi-year transformation:

• Revenue Momentum: Q1 2025 revenue reached $168.0M (+8% year-over-year), outpacing sector averages for mature diagnostic peers. Management guidance for 2025 calls for $747M to $759M in revenue (+13–15%), a clear indicator of accelerating top-line growth.
• Operational Improvement: Adjusted EBITDA surged to $7.1M, more than doubling from the previous year. Though the company remains loss-making (EPS TTM: -$0.61), operational leverage and efficiency initiatives are bearing fruit.
• Valuation Dynamics: While the lack of net profitability renders price/earnings ratios inapplicable, Neo’s price-to-sales multiple now reflects a structurally discounted biotech, trading well below sector medians following the recent de-rating—an inflection point often preceding rerating as margins recover.
• Competitive Moat: Neo enjoys leading US market share in cancer diagnostics, powered by a nationwide (and growing UK) lab network, robust genomic analysis capabilities, and deep-rooted relationships with oncologists, academic centres, and pharmaceutical sponsors.

Consensus estimates anticipate a return to sustainable profitability in coming quarters, driven by higher-margin product launches and continued operational gains. Combined with structural strengths—scale, brand, data, and regulatory know-how—the fundamental underpinnings justify renewed investor interest.

Volume and Liquidity

NEO’s liquidity profile remains robust and highly attractive for both long-term investors and active traders:

• Sustained High Volume: The three-month average daily volume of 2.06M shares is well above typical mid-cap biotech peers, ensuring ample entry and exit points and accommodating larger institutional orders without distorting price action.
• Dynamic Float: With 127.02M shares in the free float and an astonishing 100.72% institutional holding rate, market confidence in the company’s ultimate recovery is unmistakable. This institutional sponsorship generally supports dynamic revaluation during periods of positive newsflow or sentiment change.

These factors combine to offer a fertile trading ground, particularly for those seeking a volatile but liquid vehicle aligned with fundamental improvement.

Catalysts and Positive Outlook

Several tangible business catalysts set NEO apart as a stock with the potential to re-rate significantly in the year ahead:

• Ongoing Rollout of PanTracer and New Genomic Assays: The PanTracer series is expected to materially enhance the scope and accuracy of cancer detection, driving share gains in a rapidly expanding diagnostics market.
• Operational Efficiency Drive: Under new CEO Chris Zook, initial restructuring and process streamlining measures are beginning to translate into margin expansion and better cash flow management.
• Sector Momentum: The global trend towards genomic-driven personalised medicine, coupled with continued healthcare digitisation, is tailwind for NEO’s test volume growth.
• Pipeline Expansion and Strategic Partnerships: Collaborations with pharmaceutical companies deepen Neo’s connection to clinical trials and translational oncology work, expanding both innovation opportunities and durable, recurring revenues.
• ESG Leadership: As a provider focused on life-saving diagnostics, Neo enjoys a positive ESG profile—a growing point of focus for global institutional investors and funds.

The confluence of these drivers, alongside an attractive risk-reward at current valuation and strategic inflection catalysed by new leadership, lays the groundwork for a renewed positive trajectory.

Investment Strategies

Markets rarely offer a second chance at technical and fundamental lows, but NeoGenomics appears to be a textbook scenario:

• Short-Term Perspective:
• Entry at or near the recent support around $6.08 leverages potential for a short-covering bounce or momentum-driven reversion if technical resistance is breached.
• Upcoming catalysts such as earnings beats, positive guidance reiterations, or further product adoption milestones could fuel rapid price appreciation.
• Medium-Term View:
• Investors may look to accumulate through market volatility, capitalising on any dips below moving averages, with an eye towards anticipated revenue inflection and margin improvement.
• Positive sector news, as well as peer rerating, could also serve as additional tailwinds.
• Long-Term Outlook:
• For those prepared to withstand above-average volatility, Neo offers strategic exposure to the high-growth, innovation-driven cancer diagnostics sub-sector, with significant upside potential as profitability normalises and leadership executes on operational promises.

Ideal positioning may be achieved by gradually building a stake near current technical supports or ahead of major company events—such as upcoming results—and pairing with appropriate risk controls.

Is It the Right Time to Buy NeoGenomics?

A synthesis of key signals points to a stock poised for renewed consideration:

• Leading market position in cancer diagnostics, with advanced innovation and clinical integration.
• Strong 2025 growth guidance (+13–15%) and notable EBITDA recovery.
• Management confidence manifested by insider buying and fresh leadership.
• Deep institutional sponsorship and ample liquidity.
• Attractive price levels following a deep correction, with technical support suggesting limited near-term downside.

While volatility and losses persist in the short term, NeoGenomics appears to offer an excellent opportunity for patient investors and tactical traders alike, with fundamentals and multiple imminent catalysts supporting the case for a turnaround. As always, any investment decision warrants prudent due diligence and consideration of personal risk parameters—but the evidence increasingly indicates that NeoGenomics stock may be entering a new bullish phase, making it a name to watch closely in the dynamic healthcare innovation landscape.

For investors seeking differentiated exposure to the intersection of oncology, data science, and precision medicine, NEO’s current profile seems to represent an excellent opportunity to participate in a sector primed for structural expansion and breakthrough innovation.

How to buy Neo stock in Ireland?

Buying NeoGenomics (NEO) Stock Online: Easy and Secure

It’s easier than ever for investors in Ireland to buy NeoGenomics (NEO) shares online through a regulated broker. This process is both safe and accessible, using platforms authorised by international and European regulators. You have two main options: purchasing NEO shares directly (“spot buying”) for long-term ownership, or trading price movements with derivatives like CFDs (Contracts for Difference), which allow leveraged positions. Each method has distinct benefits and risks. To help you get started, you’ll find a detailed broker comparison further down the page, allowing you to choose the option best suited to your needs.

Spot buying

When you buy NeoGenomics shares for cash (“spot buying”), you become the direct owner of the company’s stock, entitled to any shareholder rights. This method is straightforward: you place a buy order with your broker, who charges a modest fixed commission per transaction (typically €4–€7 in Ireland, quoted in EUR or USD if dealing with US stocks).

Example

If the NeoGenomics (NEO) share price is $7.37 and you invest $1,000 (approx. €925), you can buy around 135 shares after accounting for a typical brokerage fee of $5.

Gain scenario: If the share price rises by 10%, your shares are now valued at $1,100.

Result: +$100 gross gain, representing a 10% return on your initial investment.

Trading via CFD

CFD (Contract for Difference) trading lets you speculate on NeoGenomics’ share price without owning the underlying stock. CFDs allow you to use leverage (magnifying both gains and losses) and to profit from rising or falling prices. Fees typically include a small spread (the difference between buy and sell price) and, for positions held overnight, daily financing charges.

Example

You invest $1,000 in a CFD position on NEO, with 5x leverage. This provides $5,000 of market exposure.

Gain scenario: If NEO’s share price climbs by 8%, your leveraged position delivers an 8% × 5 = 40% change.

Result: +$400 gross gain on your $1,000 investment (excluding fees and financing costs).

Final advice

It’s important to carefully compare the fees, trading conditions, and security of each broker before investing in NeoGenomics shares, since costs and features can vary significantly between platforms. Spot buying suits those who prefer to own shares outright, while CFD trading appeals to investors seeking short-term opportunities and leverage. The right choice depends on your investment goals and risk profile. For a clear overview of fees and available brokers, consult the comparison table found further down this page.

Our 7 tips for buying Neo stock

The latest news about Neo

NeoGenomics has reported robust quarterly revenue growth of 8% and a 102% improvement in adjusted EBITDA. For the first quarter of 2025, the company posted revenues of $168 million, up 8% compared to the previous year, and adjusted EBITDA improved to $7.1 million—a more than doubling versus Q1 2024. This performance is indicative of ongoing operational improvements, even though revenues were slightly below consensus expectations. The steady revenue increase reflects resilient demand for NeoGenomics’ specialised cancer diagnostics, an area of growing interest among Irish healthcare stakeholders invested in innovative oncology solutions.

NeoGenomics’ leadership transition signals a renewed focus on operational performance and market expansion. The appointment of Chris Zook as CEO in April 2025 marks a significant leadership change intended to drive further growth and profitability. Executive share purchases in the wake of this transition underscore leadership’s confidence in the company’s strategic direction. For investors and professional analysts in Ireland, this strengthened governance stance supports a more robust outlook for mid- and long-term share price recovery.

The launch of the PanTracer test family at ASCO 2025 highlights NeoGenomics’ ongoing product innovation. Unveiled at the prestigious American Society of Clinical Oncology (ASCO) 2025 meeting, the PanTracer family represents NeoGenomics’ latest advance in precision oncology diagnostics. These innovations could drive higher adoption from both US and UK medical providers—relevant to Irish institutions and professionals engaging in cross-border healthcare collaboration or sourcing cutting-edge oncology tests for local patients.

Analyst consensus remains constructive, with target prices above current levels and a projected 13-15% revenue growth for 2025. Current analyst targets average $10.62—about 44% above the recent share price—and forward guidance expects 13-15% top-line growth with adjusted EBITDA anticipated at up to $58 million. This outlook underlines confidence in NeoGenomics’ market positioning and its potential to capture sustained growth in precision cancer diagnostics, a trend that has meaningful resonance among Irish institutional investors seeking diversification in high-impact healthcare subsectors.

NeoGenomics maintains a strategic presence in both the UK and US, aligning with Ireland’s evolving healthcare landscape. The company’s laboratories and partnerships in the United Kingdom increase the accessibility of its advanced tests within Europe, facilitating potential collaboration with Irish healthcare providers and research centres. This proximity could support the rollout of genomic cancer diagnostics in Ireland, positioning local stakeholders to benefit from NeoGenomics’ specialized expertise and innovation pipeline.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.